Monoclonal antibodies (mAbs) have transformed modern medicine [1]. However, their impact is limited as they are not accessible to all. In 2020 IAVI and Wellcome published a joint report “Expanding access to monoclonal antibody — based products: a global call to action” [2] which highlighted the gaps and opportunities to expand access to mAbs in low- and middle-income countries (LMICs). The report revealed that few, if any, mAbs were available in LMICs,